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BACKGROUND: Knowledge of the prevalence of type-specific human papillomavirus (HPV) infections is necessary to predict the expected,
and to monitor the actual, impact of HPV immunisation and to design effective screening strategies for vaccinated populations.
METHODS: Residual specimens of cervical cytology (N¼4719), CIN3/CGIN and cervical cancer biopsies (N¼1515) were obtained from
sites throughout England, anonymised and tested for HPV DNA using the Linear Array typing system (Roche).
RESULTS: The prevalence of HPV 16 and/or 18 (with or without another high-risk (HR) type) was 76% in squamous cell carcinomas, 82%
in adeno/adenosquamous carcinomas and 63% and 91% in CIN3 and CGIN, respectively. Of all HR HPV-infected women undergoing
cytology, non-vaccine HPV types only were found in over 60% of those with mild dyskaryosis or below, and in o20% of those with
cancer. In women of all ages undergoing screening, HR HPV prevalence was 16% and HPV 16 and/or 18 prevalence was 5%.
CONCLUSION: Pre-immunisation, high-grade cervical disease in England was predominantly associated with HPV 16 and/or 18, which
promises a high impact from HPV immunisation in due course. Second-generation vaccines and screening strategies need to consider
the best ways to detect and prevent disease due to the remaining HR HPV types.
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A wide range of international studies have found approximately
70% of cervical cancers to be associated with human papilloma-
virus (HPV) types 16 or 18, and therefore preventable by currently
available HPV vaccines (Clifford et al, 2003; Mun ˜oz et al, 2004).
The United Kingdom introduced an HPV immunisation pro-
gramme in September 2008 and expects to see a consequent
decline in cervical cancers and cervical intraepithelial neoplasia in
the coming decades (Choi et al, 2009).
In 2006, almost 3000 women were diagnosed with cervical cancer
in the United Kingdom, and there were around 1000 deaths (Cancer
Research UK, 2009). It has been estimated that cervical screening
prevents at least 70% of cases that would occur without screening
(Sasieni et al, 2003). To achieve this, the NHS Cervical Screening
Programme (NHS CSP) in England screens more than 3 million
women aged 25–64 years annually and refers more than 100000 to
colposcopy examination (The NHS Information Centre, 2009).
Several studies have investigated HPV prevalence in women attending
for cervical screening in the United Kingdom (Cuschieri et al, 2004;
Kitchener et al, 2006; Hibbitts et al, 2008) and have provided valuable
data regarding the frequency of HPV infection. These studies have been
conducted in specific areas of the country, at different times, using
different testing methods, and as they have sampled all women attending
for screening they have inevitably provided fewer data regarding the
rarer disease-grades, and some age-groups.
Better knowledge of HPV type-specific prevalence and distribution
at each stage of cervical disease and among women of different ages
would both improve estimates of the expected impact from HPV
16/18 immunisation and inform planning of possible future screening
services, particularly those using HPV testing.
The aim of this study was to provide robust baseline estimates of
the prevalence and distribution of HPV types among a nationally
representative sample of women, for the full age range undergoing
screening (25–64 years) and for each disease phase (from normal
cytology to cervical cancer), prior to any impact of the National
HPV Immunisation Programme.
MATERIALS AND METHODS
Sample collection and processing
Two sample types were included in the study: (i) tissue sections
from routinely obtained diagnostic biopsies of cervical cancers and Received 9 March 2010; revised 10 May 2010; accepted 26 May 2010
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shigh-grade precancerous lesions archived in NHS pathology
laboratories, and (ii) residual liquid-based cytology (LBC) samples
from women attending for cervical screening. Samples were
obtained from eight participating NHS pathology laboratories in
England. Three laboratories (Gateshead Health NHS Foundation
Trust, Birmingham Women’s NHS Foundation Trust and Royal
Free Hampstead NHS Trust (London)) provided both tissue
sections and LBC samples, three laboratories (Central Manchester
University Hospitals NHS Foundation Trust, Sheffield Teaching
Hospitals NHS Foundation Trust and Barts and The London NHS
Trust) provided tissue sections only and two laboratories
(Gloucestershire Hospitals NHS Foundation Trust and Norfolk
and Norwich University Hospitals NHS Foundation Trust)
provided LBC samples only.
Cancer and CIN3/CGIN biopsies Sections from archived blocks of
cervical intraepithelial neoplasia 3 (CIN3), cervical glandular
intraepithelial neoplasia (CGIN), squamous cell carcinoma (SCC)
and adenocarcinoma (including adeno-squamous carcinoma)
(ADC) tissue were collected from the six participating sites
between June 2006 and July 2008. Cases were deemed suitable
for inclusion in the study after confirmation of the pathological
diagnosis by an experienced subspecialist gynaecological histo-
pathologist at each of the six participating centres. The biopsies of
cancer had been originally embedded between 1986 and 2008; 96%
had been embedded since 2000. The CIN3 and CGIN biopsies had
been collected between 2000 and 2008. Approximately six 10m
thick sections from each tissue block were placed in a 1.6ml
Eppendorf tube. A further section was stained and re-examined by
the pathologist to confirm the presence of diseased tissue. To
prevent cross-contamination from residual wax from the previous
block, the microtome blade was cleaned with ethanol between
blocks. Tissue sections were sent to the Department of Clinical
Virology, Central Manchester University Hospitals NHS Founda-
tion Trust for HPV genotyping. The following data were collected
on a study record for each sample and sent to Manchester: month
and year of birth, date of sample collection, type of lesion (CIN3,
CGIN or cancer) and histology result.
Tissue sections were de-waxed by adding a 1ml of octane
to each Eppendorf tube followed by 75ml of methanol. Tubes
were vortexed and incubated at 561C for 30min followed by
centrifugation at 13000r.p.m. for 1min after which the octane
layer was removed using a fine-tipped Pasteur pipette. The tissue
pellet was then washed with 1.0ml of ethanol, centrifuged as before
and the ethanol removed. The tubes were then left at 561C for
30–45min to evaporate off residual ethanol. The tissue was
digested in 600–1000ml (depending on size of pellet) of proteinase
K lysis buffer containing 10mM Tris/HCl buffer pH 8.3; 1mM
EDTA, 0.5% Triton X-100, 0.002% SDS and 250mgml
–1 of
proteinase K. Tissue digestion was carried out at 561C for 72h
with constant agitation. DNA was then extracted from a 200ml
aliquot of digested tissue using the Roche MagNA Pure (Roche
Applied Science, Penzberg, Germany) automated extraction system
with an elution volume of 100ml.
LBC samples Residual LBC samples were collected prospectively
from women undergoing cervical screening between October 2007
and January 2009 at five participating sites. Stratified sampling was
used to obtain sufficient high-risk (HR) HPV-positive samples to
analyse type distribution within each combination of age-band and
cytology grade, thus a disproportionately higher number of older
women and those with more severe cytology outcomes were
sampled. Before inclusion in the study, samples were collected and
handled according to local protocols: Thinprep and Surepath LBC
systems were both in use, with samples stored at ambient
temperatures while awaiting cytological examination. After com-
pletion of cytology, residual LBC samples that matched an unmet
age-group and grade (according to the site’s stratified sampling
frame) were anonymised and sent to the Health Protection Agency
(HPA) Virus Reference Department for HPV genotyping. For
Surepath samples, the tubes (enriched sample), not the vials, were
used as the vials were found to have an inadequate amount of
cellular material. The tube approximated to levels found using
Thinprep, although with more variability. The following data were
collected on a study record for each sample and sent to the HPA:
month and year of birth, cytology result, date of sample, outward
postcode (i.e., up to the first four characters), biopsy taken (and
histology result if applicable).
1ml of each LBC sample was centrifuged for 5min at
13000r.p.m. and the cellular pellet suspended in 300ml of cold
sterile phosphate-buffered saline. After a lysis step (addition of
40ml Qiagen Protease and 265ml Qiagen Buffer AL containing
guanidine hydrochloride) samples were stored at  251C before
nucleic acid extraction. Nucleic acid extraction was conducted on
the BioRobot Universal platform (Qiagen, Crawley, West Sussex,
UK) using the QIAamp DNA Blood BioRobot MDx kit and the
extraction protocol QIAamp ‘One for All UNIV rcV23’.
HPV Genotyping
A5 0ml aliquot of the extracted DNA from the biopsy samples and a
10ml aliquot of the extracted DNA from the LBC samples (i.e.,
approximately 10% of the original 1ml material, equal to the
suggested input for the Roche Linear Array (LA) test (Roche
Molecular Systems, Inc., Branchburg, NJ, USA)) was used for the
PCR reaction stage of the Roche LA test. The Roche LA test was used
according to manufacturer’s instructions, with the exception of the
sample extraction methods described above. Individual oligonucleo-
tide capture probes enabled identification of 37 HR and low-risk
HPV genotypes and the b-globin amplicon acted as a control for cell
adequacy, extraction and amplification. Identification of HPV 52 in
this system was possible by the use of a cross-reactive oligonucleo-
tide probe (52M) that hybridises with HPV genotypes 33, 35, 52 and
58. The presence of HPV 52 was therefore inferred by reactivity to
the 52 M probe with no reactivity to the individual oligonucleotide
probes representing HPV 33, 35 and 58. The presence of a
co-infection of 52 with 33, 35 or 58 would not have identified HPV
52. The HPV-positive and -negative controls provided within the
Roche LA test kit were included for every 46 tissue section samples
and every 22 LBC samples tested. The time from LBC sample
collection to receipt at HPA (median 27 days, inter-quartile range
21–35) was not negatively associated with detection of b-globin or
HPV DNA: this variable was not considered further.
Following an assessment of type-specific assay reproducibility
(details in Supplementary online material) only those bands that
gave a signal equal to or greater than the b-globin low control band
were recorded.
For tissue section samples only, additional analysis using
the Inno-Lipa Extra (Microgen Bioproducts Ltd, Camberley,
Surrey, UK) genotyping assay was performed on those samples
that were b-globin negative or in which no HR HPV DNA was
detected using Roche LA test (Figure 1). The Inno-Lipa assay is a
similar format line blot assay to Roche LA (and also includes a
b-globin control), however, it amplifies a much smaller fragment
of the DNA than the Roche LA assay making it less likely to be
affected by DNA fragmentation, which may occur during tissue
fixation. A 5ml aliquot of extracted DNA was amplified and
detected according to manufacturer’s instructions.
Figure 1 shows the flow of tissue sections and LBC samples
included in the study.
Data analysis
A valid result was defined as any sample with a positive b-globin
result by either Roche LA or Inno-Lipa Extra. Only samples with a
valid HPV typing result (N¼6234, Figure 1) were included in the
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International Agency Research on Cancer classification of types,
which were at least ‘probably carcinogenic to humans’, that is,
HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 (Bouvard
et al, 2009). Five groups of HPV types were defined for the purpose
of the analysis: (i) HPV 16 and/or HPV 18 irrespective of other
types, (ii) HPV 16 and/or 18 without any other HR types, (iii) HPV
16 and/or 18 with other HR type(s) (iv) HR HPV (any one or more
type(s)) but not HPV 16 or HPV 18 and (v) any HR HPV infection.
The prevalence of HPV infection, for each group above, for each
age-group and disease-grade, was calculated with 95% confidence
intervals (CIs) that allowed for the samples being effectively
clustered through the collection from a sample of laboratories. For
the LBC samples, prevalence estimates, other than those for a
particular age-band and cytology grade, were calculated using
sampling weights based on the number of women attending for
cervical screening as part of the NHS CSP in 2007–2008. This was
necessary to estimate prevalence for the screened population as
our stratified sampling purposely selected disproportionate
numbers from each age-band and cytology-grade. To analyse
prevalence in each region, sampling weights (based on national
cervical screening data as described above) were used and applied
to samples from each laboratory separately. Differences in
prevalence by region were assessed using Pearson’s w
2 statistic.
RESULTS
Valid data and HPV results were obtained for 1515 biopsy sections
and 4719 LBC samples submitted to the study. The biopsy sections
consisted of 906 CIN3, 450 SCC, 54 CGIN and 105 ADC samples
(including 89 adeno- and 16 adenosquamous-carcinomas), while
the LBC samples were from 2452 women without cervical disease,
1051 with borderline, 697 with mild, 276 with moderate and 243
with severe dyskaryosis. The mean (s.d.) age of the women at
biopsy was 31.9 (8.1), 49.7 (16.1), 35.4 (7.8) and 45.5 (14.1) years
for CIN3, SCC, CGIN and ADC, respectively. The numbers of
samples included in the study, by participating site, are available in
Supplementary Table S1.
HR and HPV 16 and/or 18 prevalence
The prevalence of each of our defined categories of HR HPV, by
age-group and disease-grade, from normal to cancer, are shown in
Table 1. Figure 2 shows HPV 16 and/or 18 infections by disease-
grade in each age-band, while additional data by disease-grade in
each age-band are available in Supplementary Table S2. HR HPV
types were detected in 95.8% (95% CI 94.4–96.8%) and 95.2%
(95% CI 84.8–98.6%) of SCC and ADC, respectively. HPV 16
and/or 18 (alone or with other HR types) were detected in 76.4%
(95% CI 71.0–81.1%) and 81.9% (95% CI 73.2–88.2%) of SCC and
ADC, respectively, while HPV 16 and/or 18 were the only HR
types detected in 72.0% (95% CI 67.3–76.3%) and 75.2% (95% CI
64.3–83.7%) of SCC and ADC, respectively (Table 1).
In biopsies from high-grade cervical abnormalities, HR HPV
were detected in 94.2% (95% CI 87.7–97.3%) and 98.1% (95% CI
86.4–99.8%) of CIN3 and CGIN, respectively. HPV 16 and/or 18
were detected in 63.2% (95% CI 57.0–69.1%) and 90.7% (95% CI
85.0–94.4%) of CIN3 and CGIN, respectively, and were the
only HR types detected in 53.9% (95% CI 48.7–59.0%) and 83.3%
(95% CI 61.1–94.1%), of CIN3 and CGIN, respectively (Table 1).
In women of all ages undergoing screening, the prevalence of
HR HPV and of HPV 16 and/or 18 was 15.7% (95% CI 11.2–21.6%)
and 5.1% (95% CI 3.3–8.0%), respectively (Table 1). The
prevalence of HR HPV and HPV 16 and/or 18 increased with
increasing severity of cytology grade, and was higher among
younger women, within all cytology grades (more markedly in the
lower grades) (Figure 2). Among residual LBC samples from
women with severe dyskaryosis the prevalence of HR HPV ranged
from 86% in 50- to 64-year olds to 97% in 25- to 29-year olds.
Liquid-based cytology (LBC) samples Archived tissue sections
Tissue sections submitted to the
Central Manchester
University Hospitals NHS
Foundation Trust (n=1662)
LBC samples submitted to the
Health Protection Agency
Centre for Infections
(n=5007) Out of age or cytology grade
(n=21)
Missing data (n=24)
Unsuitable sample
media (n=140)
Missing data (n=2)
HPV tested using Roche Linear Array Genotyping assay (LA)
Biopsies
(n=1520)
Inhibitory result
(n=27)
Not further
tested (n=2)
Inhibitory
result (n=3)
HPV tested using
innolipa (n=182)
HPV negative
(n=44)
HPV negative
(n=44)
HPV negative
(n=2325)
HPV positive
(n=135)
HPV positive
(n=1471)
HPV positive
(n=2394)
HPV negative
(n=137)
LR/probable HR
HPV (n=20)
HR HPV positive
(n=1336)
Valid LA HPV test result
(n=4719)
House-keeping gene not
detected (n=50)
Invalid, other reason
(n=193)
LBC samples
(n=4962)
Figure 1 Sample submission and human papillomavirus (HPV) testing algorithm for archived tissue sections and residual liquid based cytology (LBC)
samples. Abbreviations: HR¼high-risk; LR¼low-risk.
HPV type-specific prevalence in women in England
R Howell-Jones et al
211
British Journal of Cancer (2010) 103(2), 209–216 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sThe prevalence of HPV 16 and/or 18 in severe dyskaryosis alone or
with other HR types showed no strong trend with age, at between
50 and 64%, with HPV 16 and/or 18 alone (without other HR
types) detected in between 29 and 45% (Figure 2). The crude
prevalence of HR HPV and of HPV 16 and/or 18 infection in the
LBC samples from women confirmed on histology examination
to have CIN3 disease was 95.0% (n¼226) and 62.6% (n¼149),
respectively. Women of all ages with moderate dyskaryosis also
Table 1 Prevalence of high risk (HR) HPV types by age-band and cervical grade for the screened population (overall, by age and by disease grade) and for
women with severe cervical abnormalities and cervical cancer.
HPV 16
and/or 18
HPV 16 and/or
18 without any
other HR types
HPV 16 and/or
18 with another
HR type
HR HPV but
not HPV 16
and/or 18
Any HR
HPV
N
a % (95% CI)
b (n) % (95% CI)
b (n) % (95% CI)
b (n) % (95% CI)
b (n) % (95% CI)
b (n)
LBC samples
c
All screened
population
4719 5.1% (3.3–8.0) 3.2% (2.0–5.1) 1.9% (1.0–3.4) 10.6% (7.2–15.3) 15.7% (11.2–21.6)
25–29 years 611 9.2% (6.1–13.7) 5.2% (3.4–7.9) 4.0% (2.2–7.0) 19.6% (14.4–26.1) 28.8% (20.8–38.3)
30–39 years 1008 6.2% (3.2–11.8) 3.6% (1.9–6.9) 2.6% (1.2–5.4) 11.7% (7.6–17.7) 17.9% (12.1–25.8)
40–49 years 1476 2.8% (1.6–4.8) 2.1% (0.8–5.3) 0.7% (0.4–1.3) 6.8% (5.7–8.1) 9.5% (8.7–10.5)
50–64 years 1463 2.7% (1.8–3.8) 2.2% (1.3–3.6) 0.5% (0.2–1.3) 6.6% (3.7–11.5) 9.3% (6.4–13.2)
Normal 2452 3.6% (2.2–5.7) 2.4% (1.4–4.1) 1.2% (0.6–2.6) 8.6% (5.8–12.5) 12.2% (9.1–16.2)
Borderline 1051 16.5% (14.3–18.9) 9.2% (6.8–12.4) 7.3% (5.9–9.0) 33.2% (27.1–40.0) 49.7% (41.1–58.4)
Mild dyskaryosis 697 25.6% (21.0–30.8) 13.5% (10.8–16.7) 12.1% (8.6–16.8) 45.5% (39.2–51.9) 71.1% (61.8–78.9)
Moderate dyskaryosis 276 49.1% (44.1–54.1) 31.6% (25.6–38.3) 17.4% (12.2–24.3) 39.1% (35.5–42.8) 88.1% (83.9–91.4)
Severe dyskaryosis 243 63.7% (56.5–70.3) 39.8% (31.1–49.2) 23.9% (19.6–28.9) 30.3% (22.9–38.9) 93.9% (89.3–96.7)
Biopsies
CIN3 906 63.2% (57.0–69.1) (573) 53.9% (48.7–59.0) (488) 9.4% (5.6–15.2) (85) 30.9% (27.4–34.6) (280) 94.2% (87.7–97.3) (853)
SCC 450 76.4% (71.0–81.1) (344) 72.0% (67.3–76.3) (324) 4.4% (2.0–9.5) (20) 19.3% (14.1–25.9) (87) 95.8% (94.4–96.8) (431)
CGIN 54 90.7% (85.0–94.4) (49) 83.3% (61.1–94.1) (45) 7.4% (1.2–34.5) (4) 7.4% (3.3–15.7) (4) 98.1% (86.4–99.8) (53)
ADC 105 81.9% (73.2–88.2) (86) 75.2% (64.3–83.7) (79) 6.7% (2.4–17.0) (7) 13.3% (6.1–26.7) (14) 95.2% (84.8–98.6) (100)
Abbreviations: ADC¼adeno and adeno-squamous carcinoma; CI¼confidence interval; CIN3¼cervical intraepithelial neoplasia 3; CGIN¼cervical glandular intraepithelial
neoplasia; HPV¼human papillomavirus; HR¼high-risk; LBC¼ liquid-based cytology; SCC¼squamous cell carcinoma.
a161 LBC samples, 133 CIN3, 2 CGIN, 5 SCC and
2 ADC from women aged o25 years.
b95% CIs were calculated allowing for samples being clustered within laboratories.
cWeighted to allow for disproportionate LBC sample
collection by age and/or cytology grade as appropriate.
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Figure 2 Prevalence of human papillomavirus (HPV) 16 and/or 18 (alone and in mixed infections with other high-risk (HR) HPV types) by cervical grade
and age band. 95% confidence intervals were calculated allowing for samples being clustered within laboratories, except where these could not be
determined because of there being no variation between laboratories (i.e. all 100% prevalence) or when all samples were from one laboratory (i.e. CIN3
samples from women aged 65þyears), when confidence intervals (one-sided 97.5% where appropriate) were calculated without allowing for clustering (*).
Abbreviations: ADC¼adeno- and adeno-squamous carcinoma; CIN3¼cervical intraepithelial neoplasia 3; CGIN¼cervical glandular intraepithelial
neoplasia; SCC¼squamous cell carcinoma.
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(69–94% and 35–58%, respectively) (Figure 2 and Supplementary
Table S2). With increasing disease-grade, there was an increasing
proportion of HPV 16 and HPV 18 in HPV-positive samples, and a
concomitant decrease in other HR HPV types (Figure 3).
Prevalence of HR HPV by region ranged from 13.3% in
Gloucestershire to 20.1% in London, while prevalence of HPV 16
and/or 18 ranged from 4.2% in Gateshead to 6.5% in London
(Table 2). Differences in prevalence by region were not statistically
significant (Pearson’s w
2 P40.05). Further exploration of HR HPV
prevalence in young women (25–29 years) with normal cytology
results also found no significant differences between regions
(data not shown).
Type-specific prevalence
HPV 16 was the most commonly detected type in all cervical grades
apart from CGIN wherein HPV 18 was the most commonly detected
type. The four next most frequently identified HPV types in the SCC
biopsy samples (in single or multiple infections) were, in descending
order, HPV 33, 45, 52 and 31. The prevalence of these six types in
cancer, precancerous lesions and normal cytology samples is shown
in Figure 4. The six most common HPV infections in women with
normal cytology were, in descending order, HPV 16, 61, 62, 53,
CP6108 and 54; HPV 18 was the nineteenth most common type
(HPV type-specific prevalence by grade of disease is available in
Supplementary Table S3).
The four HR types found most commonly in SCC biopsy samples,
after HPV 16 and 18, showed a general pattern of increasing
prevalence with increasing grade of disease although all, except HPV
45, had higher prevalence in severe grade lesions and CIN3 than in
cervical cancers (Figure 4). The age-weighted prevalence of HPV 31
and 52 peaked in samples with moderate dyskaryosis (Figure 4).
The prevalence, in the absence of HPV 16 or 18, in SCC and ADC
of selected HPV types from the A9 and A7 species, closely related
to HPV 16 and 18 respectively, is shown in Table 3. The five types
with emerging evidence of cross-protection from HPV 16/18
vaccines (HPV 31, 33, 45, 52 or 58) were found in 14.7% of SCC
and 10.5% of ADC in the absence of HPV 16 and 18.
HPV 6 and/or 11 were detected in very few LBC samples without
HR types (n¼46, 0.8% weighted prevalence). Of these samples,
34.8% (n¼16) had normal cytology, 30.4% (n¼14) had border-
line and 34.8% (n¼16) had mild dyskaryosis. No women with
moderate or severe dyskaryosis were found to have HPV 6 and/or
11 without a HR HPV type. Overall (irrespective of other types),
the age-weighted (to NHS CSP population) prevalence of HPV 6
and/or 11 was 0.9% (95% CI 0.6–1.5%) in normal samples, 0.1%
(95% CI 0.08–0.14%) in borderline samples, 0.1% (95% CI 0.05–
0.3%) in mild dyskaryotic samples, 0.02% (95% CI 0.01, 0.1%) in
moderate dyskaryotic and 0.01% (95% CI 0.0, 0.04%) in severe
dyskaryotic samples. In women with normal cytology, the
weighted prevalence of HPV 6 was 0.8% and HPV 11 was 0.2%
(Supplementary Table S3).
DISCUSSION
We have used anonymous, residual, cervical cytology (LBC)
samples and biopsies of cervical cancers and high-grade lesions,
collected from eight sites, to describe type-specific HPV prevalence
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Figure 3 Proportional Venn diagrams showing human papillomavirus (HPV) 16, HPV 18 and high-risk (HR) types other than HPV 16 or HPV 18 (OHR)
in HR HPV-positive samples, by cervical grade (Chow and Rodgers, 2005). Red: HPV 16; green: HPV 18; blue: OHR; yellow: HPV 16 and HPV 18; pink: HPV
16 and OHR; turquoise: HPV 18 and OHR; white: HPV 16, 18 and OHR. *Age-weighted percentages (to allow for disproportionate liquid-based cytology
sample collection by age). Abbreviations: ADC¼adeno- and adeno-squamous carcinoma; CIN3¼cervical intraepithelial neoplasia 3; CGIN¼cervical
glandular intraepithelial neoplasia; SCC¼squamous cell carcinoma.
Table 2 HR and HPV 16 and/or 18 prevalence by region (submitting laboratory) in women undergoing cervical screening
Prevalence
a (95% CI)
Submitting laboratory Sample type N (%) HR HPV HPV 16 and/or 18
Birmingham (BW) Surepath 1019 (21.6) 13.8 (11.3–16.7) 4.4 (3.1–6.2)
Gateshead (GH) Surepath 1063 (22.5) 16.9 (14.3–19.9) 4.2 (3.0–5.9)
Gloucestershire (GL) Thinprep 927 (19.6) 13.3 (10.4–16.9) 6.4 (4.6–6.6)
Norfolk (NN) Thinprep 1077 (22.8) 16.2 (13.4–19.4) 6.2 (4.6–8.4)
London (RF) Thinprep 633 (13.4) 20.1 (15.1–26.2) 6.5 (3.8–10.8)
P¼0.0709
b P¼0.3809
b
Abbreviations: BW¼Birmingham Women’s NHS Foundation Trust; CI¼confidence interval; GH¼Gateshead Health NHS Foundation Trust; GL¼Gloucestershire Hospitals
NHS Foundation Trust; NN¼Norfolk and Norwich University Hospitals NHS Foundation Trust; RF¼Royal Free Hampstead NHS Trust (London).
aAll prevalence estimates
weighted for each laboratory to allow for differences between age and cytology distribution in study sample vs national population.
bPearson’s w
2.
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pathology, from normal to cancer.
Assuming the relative frequency of SCC and ADC in our
study are representative of all cervical cancers, our results
suggest that at least 73% of cervical cancers in England are
potentially preventable by type-specific protection from HPV
16/18 immunisation (i.e., are infected with HPV 16 and/or 18
only), rising to around 77% if co-infection with other HR types is
never the causative HPV infection. Similarly, at least 56% and up
to 65% of CIN3/CGIN are potentially preventable by HPV 16/18
immunisation. The difference between the percentage of cases with
HPV 16 and/or 18 only (minimum attributable fraction), and the
percentage with HPV 16 and/or 18 and another HR HPV (probable
attributable fraction), indicates the potential for unmasking of
disease caused by other HR HPV types if HPV 16 and 18 infections
are prevented. By the same reckoning, between 32 and 49% of
the moderate and 40 and 64% of the severe dyskaryotic cervical
abnormalities identified by cervical screening may be preventable
by HPV 16/18 immunisation.
HPV 31 and 45 were each associated (without HPV 16 and/or 18,
but with or without other HR types) with an additional 3% of SCC
and 2% of ADC. As there is some evidence of cross-protection
from current HPV 16/18 vaccines against infection and disease due
to these types and HPV 33, 52 and 58, which are closely related to
HPV 16 or HPV 18 (Brown et al, 2009; Paavonen et al, 2009), the
benefits of immunisation may include reduction in these cancers
also. If cross-protection against HPV 31, 33, 45, 52 and 58 ranges
from 25 to 29%, as suggested currently by clinical trials (Brown
et al, 2009; Paavonen et al, 2009), our findings suggest that HPV
16/18 immunisation may prevent an additional 3–4% of cervical
cancers in England.
Other studies of HPV type distribution in cervical cancers in the
United Kingdom have reported similarly high fractions of cases
probably attributable to HPV 16 and/or 18. Cuzick et al (2000)
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Figure 4 Human papillomavirus (HPV) prevalence by cervical grade of the six most common types found in squamous cell carcinoma (SCC) biopsies.
*Age-weighted prevalence (to allow for disproportionate liquid-based cytology sample collection by age). Abbreviations: ADC¼adeno- and adeno-
squamous carcinoma; CIN3¼cervical intraepithelial neoplasia 3; CGIN¼cervical glandular intraepithelial neoplasia.
Table 3 Prevalence of selected A9 and A7 types in squamous cell carcinoma (SCC) and adeno- and adeno-squamous carcinoma (ADC), with and
without human papillomavirus (HPV) 16 and 18
SCC ADC
Species HPV type
Prevalence in the
absence of HPV 16
and HPV 18 (95% CI)
a (n) Prevalence (n)
Prevalence in the
absence of HPV 16
and HPV 18 (95% CI)
a (n) Prevalence (n)
A9 31 2.9% (1.5–5.4) (13) 3.1% (14) 1.9% (0.2–17.6) (2) 1.9% (2)
33 5.3% (3.7–7.7) (24) 5.8% (26) 4.8% (1.7–12.9) (5) 4.8% (5)
52 3.1% (2.1–4.6) (14) 3.6% (16) 1.9% (0.6–6.3) (2) 3.8% (4)
58 0.4% (0.1–2.2) (2) 0.9% (4) 0.0% (0.0–6.6)* (0) 0.0% (0)
A7 45 3.3% (1.6–6.6) (15) 4.2% (19) 1.9% (0.6–6.3) (2) 2.9% (3)
39 1.8% (0.8–4.1) (8) 2.2% (10) 1.0% (0.1–6.5) (1) 1.9% (2)
HPV 31, 33, 39, 45 or 52
b 15.8% (11.0–22.2) (71) 18.2% (82) 11.4% (4.5–25.9) (12) 15.2% (16)
HPV 31, 33, 45, 52 or 58
c 14.7% (9.3–22.3) (66) 17.1% (77) 10.5% (4.3–23.2) (11) 13.3% (14)
a95% confidence intervals were calculated allowing for samples being clustered within laboratories except where these could not be determined because of no variation between
laboratories (i.e., all 0% prevalence), when one-sided 97.5% confidence intervals have been calculated (*).
bFive most common types in SCC after HPV 16 and 18.
cTypes against
which some cross-protection efficacy results have been reported from clinical trials (Paavonen et al, 2009; Brown et al, 2009).
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and found HPV 16 and/or 18 in 78% of SCC and 71% of ADC
(including adenocarcinoma and adeno-squamous carcinoma).
In Scotland, Tawfik El-Mansi et al (2006) found HPV 16 and/or
18 in 61% of ADC diagnosed between 1991 and 2001, and Cuschieri
et al (2010) detected HPV 16 and/or 18 in 72% of 370 invasive
cervical cancers diagnosed up to 2004. In Wales, Powell et al (2009)
found HPV 16 and/or 18 in 80% of SCC (N¼222) and 91% of ADC
(N¼47) diagnosed between 2000 and 2006. Three other studies
have looked at fewer than 50 cases each (Crook et al, 1992; Arends
et al., 1995; Giannoudis et al, 1999). The differences between these
United Kingdom-based studies may reflect differences in HPV
typing methods, and/or chance, and do not suggest significant
variations between countries in the contribution of HPV 16 and/or
18 to cervical cancer incidence that are likely to have important
effect on the impact of immunisation.
Our results are consistent with previous suggestions that a
higher proportion of disease in Europe will be preventable by
current HPV 16/18 vaccines than some other areas of the world
(Mun ˜oz et al, 2004; Li et al, 2010), mostly because of higher HPV
16 prevalence. Furthermore, the most common non-vaccine types
identified in our study (HPV 33, 45, 52 and 31) were among the
most common types found in international studies, albeit not in
exactly the same ranking (Clifford et al, 2003; Mun ˜oz et al, 2004;
Li et al, 2010).
Several studies have reported data on HPV prevalence in women
attending for cervical screening in the United Kingdom (Cuschieri
et al, 2004; Peto et al, 2004; Kitchener et al, 2006; Hibbitts et al,
2008). In England, HR HPV prevalence of 16% (samples collected
between 2001 and 2003) (Kitchener et al, 2006) and 7% (samples
collected between 1988 and 1993) (Peto et al, 2004) have previously
been reported from studies conducted in Manchester. In south
Wales (2008), HR HPV prevalence of 11% has been reported
(Hibbitts et al, 2008), while in Scotland (2004), HR HPV prevalence
of 16% has been reported (Cuschieri et al, 2004). In our study, the
weighted (by age and cytology grade) prevalence of HR HPV was
16% (95% CI 11–22). These studies from across the United
Kingdom also report fairly consistent results with respect to the
prevalence of HPV 16 and/or 18. Differences in the age range, HPV
typing methods, sample types and chance variation may account
for some differences between studies. Differences may also reflect
increases in prevalence over time, as the lowest HR HPV
prevalence (7%) was found in the earliest study (Peto et al,
2004), over a period when there has been an increasing frequency
of clinically apparent HPV 6 and 11 infection as cases of genital
warts (Health Protection Agency, 2008).
Strengths of our study include collection of both LBC samples
and biopsy samples from a number of sites geographically spread
across England, and testing for the same HPV types. The stratified
sampling of LBCs from each centre enabled the description of
type-specific infection in more severe cytology abnormalities and
from older women.
This was a cross-sectional study of a disease state that spans
a long time course of progression from infection to cancer:
when comparing the type distribution in cancers and in lower
grade disease we cannot therefore rule out any affect from
the profile of HPV types in the population changing over
time. Unfortunately, data on ethnicity, deprivation and sexual
behaviour were not available with our samples and therefore the
association between these factors and HPV prevalence could not
be analysed.
Our estimates of prevalence are based on cervical screening.
As repeat screens from individuals were not excluded and may
be expected to have a higher HPV prevalence, our estimates
may overestimate population prevalence among screened women
(as do those from other similar studies of cervical screens).
Our prevalence estimates do not provide data on the 20% of the
population who do not regularly attend for screening (The NHS
Information Centre, 2009), and who would have more to gain from
immunisation.
This is the first study to describe comprehensively type-specific
HPV prevalence across England, including samples from women
with normal cytology and all stages of cervical disease in order to
be able to estimate the proportion of disease potentially
preventable, nationally, by immunisation. These data will be used
in models to assess the likely benefit from HPV immunisation
(Jit et al, 2008; Choi et al, 2009), and as baseline data against
which to evaluate changes in type-specific HPV prevalence and
type distribution after the introduction of the HPV immunisation
programme. The findings support optimism regarding high impact
of the National HPV (16/18) Immunisation Programme on cervical
disease in England.
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